Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
17 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 29
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇰🇷 South KoreaOfficiallegal approval, dossier, workflowcurrent frameworkLatest observed: checked live
🇰🇷 South KoreaOfficialpositive list and negotiation purposepositive list from 2006-12-29Latest observed: checked live
🇰🇷 South KoreaOfficialsequence, omission, expansion, volume triggerscurrent operational pageLatest observed: checked live
🇰🇷 South KoreaOfficialDREC role and evaluation scope2025Latest observed: published 2025
🇰🇷 South KoreaOfficialICER interpretation and non-fixed threshold2022Latest observed: 2022
🇰🇷 South KoreaOfficialRSA purpose, scope, refund, volume policyeffective 2013-12-31Latest observed: 2013-12-30
🇰🇷 South KoreaOfficialflexible contract, reassessment, generics, lifecycle reformdecision 2026-03-26Latest observed: checked live
🇰🇷 South KoreaOfficialcurrent approval context; not used for pathway rulesreport 2025Latest observed: 2026-07-03
🇰🇷 South KoreaOfficialPhased commencement and selected price-adjustment transition provisions2026-07-30Latest observed: 2026-08-01
🇰🇷 South KoreaOfficialPhased commencement and selected price-adjustment transition provisions2026-07-30Latest observed: 2026-08-01
🇰🇷 South KoreaOfficialReassessment cohort and exclusion fields, dated price-list context, evidence-submission route and October 31 deadline2026-09-22Latest observed: 2026-09-22
🇰🇷 South KoreaOfficialSelected formula, premium evidence and monitoring, shortage-prevention designation, cost compensation and phased-transition rules.2026-07-30Latest observed: 2026-07-30
🇰🇷 South KoreaOfficialSelected formula, premium evidence and monitoring, shortage-prevention designation, cost compensation and phased-transition rules.2026-07-30Latest observed: 2026-07-30
🇰🇷 South KoreaOfficialSelected formula, premium evidence and monitoring, shortage-prevention designation, cost compensation and phased-transition rules.2026-07-30Latest observed: 2026-07-30
🇰🇷 South KoreaOfficialSelected formula, premium evidence and monitoring, shortage-prevention designation, cost compensation and phased-transition rules.2026-07-30Latest observed: 2026-07-30
🇰🇷 South KoreaOfficialSelected expansion and volume branches, negotiation clocks, and the meaning and publication window of negotiation status.Date not statedLatest observed: Date not stated
🇰🇷 South KoreaOfficialSelected expansion and volume branches, negotiation clocks, and the meaning and publication window of negotiation status.Date not statedLatest observed: Date not stated
🇰🇷 South KoreaOfficialSelected expansion and volume branches, negotiation clocks, and the meaning and publication window of negotiation status.Date not statedLatest observed: Date not stated
🇰🇷 South KoreaOfficialDated refund-list identity fields and the Veklury/Paxlovid benefit-only exception; not individual refund amounts.2026-10-01Latest observed: 2026-10-01
🇰🇷 South KoreaOfficialDated refund-list identity fields and the Veklury/Paxlovid benefit-only exception; not individual refund amounts.2026-10-01Latest observed: 2026-10-01
🇰🇷 South KoreaOfficialReassessment scope, cohort/exclusion tests, evidence filing, calculation branches, planned phases, premiums and litigation treatment.2026-08-31Latest observed: 2026-08-31
🇰🇷 South KoreaOfficialReassessment scope, cohort/exclusion tests, evidence filing, calculation branches, planned phases, premiums and litigation treatment.2026-08-31Latest observed: 2026-08-31
🇰🇷 South KoreaOfficialLaunch and parallel transition withv3.2.2; notice does not set mandatory v4-only date.2026-10-15Latest observed: 2026-10-15
🇰🇷 South KoreaOfficialLaunch and parallel transition withv3.2.2; notice does not set mandatory v4-only date.2026-10-15Latest observed: 2026-10-15
KR-S18 · MFDS · eCTD v4.0 service launch,15October2026
Read on Atlas · PDFOfficial source ↗Saved copy: Source: Ministry of Food and Drug Safety (MFDS), Pharmaceutical Policy Division, eCTD v4.0 service launch, 15 October 2026. Original: www.mfds.go.kr. KOGL Type 1
🇰🇷 South KoreaOfficialOperational application from June2026, public versus authorised claim-price files and provider billing. Official KHIDI text corroborates HIRA instructions; KHA hosts the notice and FAQ. Complete manufacturer eligibility and contract terms need their applicable primary notice and agreement.2026-06Latest observed: 2026-06-24
🇰🇷 South KoreaOfficialOperational application from June2026, public versus authorised claim-price files and provider billing. Official KHIDI text corroborates HIRA instructions; KHA hosts the notice and FAQ. Complete manufacturer eligibility and contract terms need their applicable primary notice and agreement.2026-06Latest observed: 2026-06-24
🇰🇷 South KoreaOfficialOperational application from June2026, public versus authorised claim-price files and provider billing. Official KHIDI text corroborates HIRA instructions; KHA hosts the notice and FAQ. Complete manufacturer eligibility and contract terms need their applicable primary notice and agreement.2026-06Latest observed: 2026-06-24
🇰🇷 South KoreaOfficialFull two-page notice: five medicine families, the orphan-medicine exception, exclusion of medicines subject to Article7(3) risk-sharing conditions, and five notification recipients. Notice dated21April2026; no separate commencement clause. June provider application is supported separately by KR-S09.2026-04-21Latest observed: 2026-04-21
🇰🇷 South KoreaOfficialFull two-page notice: five medicine families, the orphan-medicine exception, exclusion of medicines subject to Article7(3) risk-sharing conditions, and five notification recipients. Notice dated21April2026; no separate commencement clause. June provider application is supported separately by KR-S09.2026-04-21Latest observed: 2026-04-21
KR-S19 · Ministry of Health and Welfare (MOHW) · MOHW Notice2026-348: medicines eligible for a separately negotiated ceiling and authorised notification recipients
Read on Atlas · PDFOfficial source ↗Saved copy: Source: Ministry of Health and Welfare, Republic of Korea, Notice 2026-348, 21 April 2026. Exact official original; statutory exclusion for state announcements under Korean Copyright Act Article 7(2). Korean Copyright Act, Article 7(2)
For education only — not regulatory, pricing or legal advice.